N
Nicoya Lifesciences
A biotech company using nanotechnology to make scientific instruments more affordable and user-friendly, aiding scientists in their work
About Nicoya Lifesciences
Nicoya is a Canadian biotechnology company dedicated to improving human life by empowering scientists with advanced, user-friendly tools. Founded in 2012 by Ryan Denomme, Nicoya's mission is to leverage nanotechnology to enhance the affordability and ease of use of scientific instruments, making cutting-edge research more accessible to the scientific community.
Read full description
At the core of Nicoya's offerings is its innovative line of scientific instruments designed to streamline and accelerate research processes. By focusing on nanotechnology, Nicoya develops instruments that are not only highly precise and reliable but also cost-effective and easy to use. This commitment to accessibility ensures that researchers across various disciplines can benefit from state-of-the-art technology without the barriers of high costs or complex operations.
One of Nicoya's flagship products is the OpenSPR, a benchtop Surface Plasmon Resonance (SPR) instrument. SPR is a powerful technique used to study molecular interactions in real-time, providing valuable insights into biological processes and drug discovery. The OpenSPR is designed to be compact, affordable, and user-friendly, making it an ideal tool for academic labs, biotech companies, and pharmaceutical research facilities. By democratizing access to SPR technology, Nicoya enables more scientists to conduct high-quality research and drive innovation in their fields.
In addition to its hardware offerings, Nicoya provides comprehensive software solutions that complement its instruments. These software tools offer advanced data analysis and visualization capabilities, allowing researchers to interpret their results more effectively and gain deeper insights into their studies. Nicoya's software is designed to be intuitive and easy to use, ensuring that scientists can focus on their research rather than navigating complex software interfaces.
Nicoya is also committed to fostering a collaborative and supportive scientific community. The company offers educational resources, training programs, and customer support to help researchers maximize the potential of their instruments and achieve their research goals. By providing ongoing support and engagement, Nicoya ensures that scientists have the tools and knowledge they need to succeed.
With a team of experienced scientists, engineers, and industry professionals, Nicoya is dedicated to continuous innovation and improvement. The company invests in research and development to stay at the forefront of nanotechnology and scientific instrumentation, ensuring that its products remain cutting-edge and effective in addressing the evolving needs of the scientific community.
At a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Kitchener, Canada
- Employees
- 123
- Open positions
- None listed
- Dealroom signal
- 68.1/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Microfluidics, Spinout, Tech for Biotech and Pharma, Hard Tech
- Technology
- Deep Tech, Nanotech, IoT InternetOfThings
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 2 companies, latest Jun 2025
- Capital deployed
- —
- Preferred round
- ACQUISITION
Latest news
Press, funding announcements and product moves mentioning Nicoya Lifesciences.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2021 | $15M | $59M | Export Development Canada · MaRS Investment Accelerator Fund · Agilent · Garage Capital | ↗ |
| GRANT✓Other financing | Jun 2020 | $300K | — | National Research Council Canada | ↗ |
Growth signals
Latest recorded traffic for Nicoya Lifesciences is 11K monthly website visits, down 8.3% over the last three months. Nicoya Lifesciences's team declined 0.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
PhotophysicsLeatherhead, United Kingdom
→
LSK TechnologiesKitchener, CanadaLab-Quality Testing Without the Lab: Affordable Solutions for Fast and Accurate Results
$500Kvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
MaRS Investment Accelerator Fund
University of Waterloo Student Venture Fund
National Research Council Canada
Series A13 investors entered at this stage
University of Waterloo
Ripple Ventures
Laurier Start-up Fund
BDC Capital
Innovation Grade Capital
Angel One Network
NorthSpring Capital Partners
Maple Leaf Angels
FedDev Ontario
Whitecap Venture Partners
Export Development Canada
Agilent
Garage Capital
Other known investors2 additional known investors
Graphite Ventures
Velocity
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nicoya Lifesciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nicoya Lifesciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







